Long-term administration of mifepristone (RU486): Clinical tolerance during extended treatment of meningioma

Cancer Investigation

Volumn 24, Issue 8, 2006, Pages 727-733

  Grunberg, Steven M ^a,e   Weiss, Martin H ^b   Russell, Christy A ^b   Spitz, Irving M ^c   Ahmadi, Jamshid ^b   Sadun, Alfredo ^b   Sitruk Ware, Regine ^d  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c SHAARE ZEDEK MEDICAL CENTER   (Israel)

^d POPULATION COUNCIL   (United States)

^e FLETCHER ALLEN HEALTH CARE   (United States)

Author keywords

Hormonal modulation; Meningioma; Mifepristone

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; MIFEPRISTONE; TAMOXIFEN; TESTOSTERONE;

ABDOMINAL PAIN; ADRENAL INSUFFICIENCY; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ANOREXIA; ARTICLE; BREAST TENDERNESS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DRUG EFFICACY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG WITHDRAWAL; EDEMA; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM POLYP; FATIGUE; FEMALE; FOLLOW UP; FOOT EDEMA; GYNECOMASTIA; HAIR DISEASE; HOT FLUSH; HUMAN; HYPERCALCEMIA; LIBIDO; LONG TERM CARE; MALAISE; MALE; MENINGIOMA; MOOD CHANGE; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RASH; RECOMMENDED DRUG DOSE; SIDE EFFECT; TABLET; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; TREATMENT WITHDRAWAL; VISUAL FIELD; VOMITING;

ADULT; AGED; AGED, 80 AND OVER; COMBINED MODALITY THERAPY; CONTRACEPTIVES, ORAL, SYNTHETIC; FEMALE; HUMANS; MALE; MENINGEAL NEOPLASMS; MENINGIOMA; MIDDLE AGED; MIFEPRISTONE; TREATMENT OUTCOME;

EID: 33845674881     PISSN: 07357907     EISSN: 15324192     Source Type: Journal    
DOI: 10.1080/07357900601062339     Document Type: Article

References (47)

1. Winer, E.P.; Morrow, M.; Osborne, C.K.; Harris, J.R. Malignant tumors of the breast. In Cancer - Principles & Practice of Oncology, 6th Ed.; DeVita, V.T., Jr.; Hellman, S.; Rosenberg, S, Eds.; Lippincott Williams & Wilkins: Philadelphia; 2001;1651-1717.
2. Erlichman, C.; Loprinzi, C.L. Hormonal therapies. In Cancer - Principles & Practice of Oncology, 6th Ed.; DeVita, V.T., Jr.; Hellman, S.; Rosenberg, S, Eds.; Lippincott Williams & Wilkins: Philadelphia; 2001;478-488.
3. Haller, D.G.; Glick, J.H. Progestational agents in advanced breast cancer: an overview. Semin. Oncol. 1986, 13 (Suppl. 4), 2-8.
4. Loprinzi, C.L.; Ellison, N.M.; Schaid, D.J.; et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J. Natl. Cancer. Inst. 1990, 82 (13), 1127-1132.
5. Baulieu, E.E. Contragestion and other clinical applications of RU486, an antiprogesterone at the receptor. Science 1989, 245 (4924), 1351-1357.
6. Kepes, J.J. Meningiomas: Biology, Pathology, and Differential Diagnosis; Masson: New York; 1982, 17-19.
7. Weyand, R.D.; MacCarty, C.S.; Wilson, R.B. The effect of pregnancy on intracranial meningiomas occurring about the optic chiasm. Surg. Clin. North Am. 1951, 31 (4), 225-233.
8. Schoenberg, B.S.; Christine, B.W.; Whisnant, J.P. Nervous system neoplasms and primary malignancies of other sites. the unique association between meningiomas and breast cancer. Neurology 1975, 25 (8), 705-712.
9. Grunberg, S.M. The role of progesterone receptors in meningioma. In New Drugs, Concepts and Results in Cancer Chemotherapy; Muggia, F.M., Ed.; Kluwer Academic Publishers: Boston; 1992; 127-137.
10. Olson, J.J.; Beck, D.W.; Schlechte, J.; Loh, P.M. Hormonal manipulation of meningiomas in vitro. J. Neurosurg. 1986, 65 (1), 99-107.
11. Olson, J.J.; Beck, D.W.; Schlechte, J.A.; Loh, P.M. Effect of the antiprogesterone RU-38486 on meningioma implanted into nude mice. J. Neurosurg. 1987, 66 (4), 584-587.
12. Spitz, I.M.; Bardin, C.W.; Benton, L.; Robbins, A. Early pregnancy termination with mifepristone and misoprostol in the United States. N. Engl. J. Med. 1998, 338 (18), 1241-1241.
13. Spitz, I.M.; Van Look, P.F.; Coelingh Bennink, H.J. The use of progesterone antagonists and progesterone receptor modulators in contraception. Steroids 2000, 65 (10-11), 817-823.
14. Grunberg, S.M. Role of antiprogestational therapy for meningiomas. Hum. Reprod. 1994, 9 (Supp. 1), 202-207.
15. Spitz, I.M.; Grunberg, S.M.; Chabbert-Buffet, N.; Lindenberg, T.; Gelber, H.; Sitruk-Ware, R. The management of patients receiving long term treatment with mifepristone. Fertil. Steril. 2005 84 (6), 1719-1726.
16. Bryant, J.; Fisher, B.; Dignam, J. Duration of adjuvant tamoxifen therapy. J. Natl. Cancer Inst. Monogr. 2001, 30, 56-61.
17. Romieu, G.; Maudelonde, T.; Ulmann, A.; et al.; The antiprogestin RU486 in advanced breast cancer: preliminary clinical trial. Bull Cancer 1987, 74 (4), 455-461.
18. Klijn, J.C.M.; de Jong, F.H.; Bakker, G.H.; Lamberts, S.W.J.; Rodenburg, C.J.; Alexieva-Figusch, J. Antiprogestins, a new form of endocrine therapy for human breast cancer. Cancer Res. 1989, 49 (1), 2851-2586.
19. Kettel, L.M.; Murphy, A.A.; Morales, A.J.; et al. Treatment of endometriosis with the antiprogesterone mifepristone (RU486). Fertil. Steril. 1996, 65 (1), 23-28.
20. Kettel, L.M.; Murphy, A.A.; Morales, A.J.; Yen, S.S.C. Preliminary report on the treatment of endometriosis with low-dose mifepristone (RU 486). Am. J. Obstet. Gynecol. 1998, 178 (6), 1151-1156.
21. Murphy, A.A.; Morales, A.J.; Kettel, L.M.; Yen, S.S. Regression of uterine leiomyomata to the antiprogesterone RU486: dose-response effect. Fertil. Steril. 1995, 64 (1), 187-190.
22. Chu, J.W.; Matthias, D.F.; Belanoff, J.; Schatzberg, A.; Hoffman, A.R.; Feldman, D. Successful long-term treatment of refractory Cushing's disease with high-dose mifepristone (RU 486). J. Clin. Endocrinol. Metab. 2001, 86 (8), 3568-3573.
23. Chrousos, G.P.; Lauc, L.; Nieman, L.K.; Udelsman, R.; Kawai, S.; Loriaux, D.L. Clinical applications of RU 486, a prototype glucocorticoid and progesterone antagonist. In The Adrenal and Hypertension: From Cloning to Clinic; Mantero, F., Takeda, R., Scoggins, B.A., Biglieri, E.G., Funder, J.W., Eds.; Raven Press: New York; 1989, 273-284.
24. Lamberts, S.W.J.; Koper, J.W.; de Jong, F.H. The endocrine effects of long-term treatment with mifepristone (RU486). J. Clin. Endocrinol. Metab. 1991, 73 (1), 187-191.
25. Heikinheimo, O.; Ranta, S.; Grunberg, S.; Lahteenmaki, P.; Spitz, I.M. Alterations in the pituitary-thyroid and pituitary-adrenal axes - consequences of long-term mifepristone treatment. Metabolism 1997, 46 (3), 292-296.
26. Bertagna, X.; Escourolle, H.; Pinquier, J.L.; et al. Administration of RU 486 for 8 days in normal volunteers: antiglucocorticoid effect with no evidence of peripheral cortisol deprivation. J. Clin. Endocrinol. Metab. 1994, 78 (2), 375-380.
27. Wolkowitz, O.M.; Reus, V. I. Treatment of depression with antiglucocorticoid drugs. Psychosom. Med. 1999, 61 (5), 698-711.
28. Murphy, B.E.; Filipini, D.; Ghadirian, A.M. Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J. Psychiatry Neurosci. 1993, 18 (5), 209-213.
29. Belanoff, J.K.; Flores, B.H.; Kalezhan, M.; Sund, B.; Schatzberg, A. F. Rapid reversal of psychotic depression using mifepristone. J. Clin. Psychopharmacol. 2001, 21 (5), 516-521.
30. Shariff, S.; Cumming, C.E.; Lees, A.; Handman, M.; Cumming, D.C. Mood disorder in women with early breast cancer taking tamoxifen, an estradiol receptor antagonist. An expected or unexpected effect? Ann. NY Acad. Sci. 1995, 761, 365-368.
31. Day, R.; Ganz, P.A.; Costantino, J. P. Tamoxifen and depression: more evidence from the National Surgical Adjuvant Breast and Bowel Project's Breast Cancer Prevention (P-1) Randomized Study. J. Natl. Cancer Inst. 2001, 93 (21), 1615-1623.
32. Morales, A.J.; Kettel, L.M.; Murphy, A.A. Mifepristone: clinical application in general gynecology. Clin. Obstet. Gynecol. 1996, 39 (2), 451-460.
33. Martineau, P.A.; Levental, M. Large endometrial polyp in a patient on long-term mifepristone therapy. J. Ultrasound Med. 2000, 19 (7), 487-489.
34. Newfield, R.S.; Spitz, I.M.; Isacson, C.; New, M.I. Long-term mifepristone (RU486) therapy resulting in massive benign endometrial hyperplasia. Clin. Endocrinol. 2001, 54 (3), 399-404.
35. De Keizer, R.J.W.; Smit, J.W.A. Mifepristone treatment in patients with surgically incurable sphenoid-ridge meningioma: a long-term follow-up. Eye 2004, 18 (9), 954-958.
36. Grunberg, S.M.; Rankin, C.; Townsend, J.; et al. Phase III double-blind randomized placebo-controlled study of mifepristone for the treatment of unresectable meningioma. Proc. Am. Soc. Clin. Oncol. 2001, 20, A222.
37. Murphy, A.A.; Kettel, L.M.; Morales, A.J.; Roberts, V.; Parmley, T.; Yen, S.S. Endometrial effects of long-term low-dose administration of RU486. Fertil. Steril. 1995, 63 (4), 761-766.
38. Croxatto, H.B.; Kovacs, L.; Massai, R.; et al. Effects of long-term low-dose mifepristone on reproductive function in women. Hum. Reprod. 1998, 13 (4), 793-798.
39. Brown, A.; Cheng, L.; Lin, S.; Baird, D.T. Daily low-dose mifepristone has contraceptive potential by suppressing ovulation and menstruation; a double-blind randomized control trial of 2 and 5 mg per day for 120 days. J. Clin. Endocrinol. Metab. 2002, 87 (1), 63-70.
40. Fisher, B.; Costantino, J.P.; Redmond, C.K.; Fisher, E.R.; Wickerham, D.L.; Cronin, W.M. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J. Natl. Cancer Inst. 1994, 86 (7), 527-537.
41. Brown, K. Breast cancer chemoprevention: risk-benefit effects of the antioestrogen tamoxifen. Expert Opin. Drug Saf. 2002, 1 (3), 253-267.
42. Suh-Burgmann, E.J.; Goodman, A. Surveillance for endometrial cancer in women receiving tamoxifen. Ann. Intern. Med. 1999, 131 (2), 127-135.
43. Machado, F.; Rodriguez, J.R.; Leon, J.P.; Rodriguez, J.R.; Parrilla, J.J.; Abad, L. Tamoxifen and endometrial cancer. Is screening necessary? A review of the literature. Eur. J. Gynaecol. Oncol. 2005, 26 (3), 257-265.
44. Grunberg, S.M.; Weiss, M.H. Lack of efficacy of megestrol acetate in the treatment of unresectable meningioma. J. Neurooncol. 1990, 8 (1), 61-65.
45. Moss, J.; DcCastro, R.; Patronas, N.J.; Taveira-DaSilva, A. Meningiomas in lymphangioleiomyomatosis. JAMA 2001, 286 (15), 1879-1881.
46. Lesch, K.P.; Schott, W.; Engl, H.G.; Gross, S.; Thierauf, P. Gonadal steroid receptors in meningiomas. J. Neurol. 1987, 234 (5), 328-333.
47. Koper, J.W.; Fockens, J.A.; Braakman, R.; Lamberts, S.W.J. Effects of progesterone on the response to epidermal growth factor and other growth factors in cultured human meningioma cells. Cancer Res. 1990, 50 (9), 2604-2607.